LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$3.05
-0.15 (-4.69%)
Open$3.12
Previous Close$3.20
Day High$3.21
Day Low$2.96
52W High$6.42
52W Low$2.72
Volume—
Avg Volume2.03M
Market Cap365.15M
P/E Ratio—
EPS$-2.08
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+663.0% upside
Current
$3.05
$3.05
Target
$23.27
$23.27
$16.60
$23.27 avg
$30.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |
| Rev Growth | -5.1% | +17.2% | +14.9% |
| Debt/Equity | 0.69 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |